Merck unveiled encouraging Phase 3 KEYNOTE-689 trial results for KEYTRUDA at the AACR 2025 Meeting, sparking investor ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two — ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.

Robert F. Kennedy Jr. and I rarely see eye to eye, but I’ll grudgingly admit he’s not entirely wrong about food dyes, though ...

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

Merck stock reversed higher Thursday, though the company reported another quarter of light sales for its HPV vaccine, ...

Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...